Literature DB >> 23406742

Effects of the histamine H₃ receptor antagonist ABT-239 on cognition and nicotine-induced memory enhancement in mice.

Marta Kruk1, Joanna Miszkiel, Andrew C McCreary, Edmund Przegaliński, Małgorzata Filip, Grażyna Biała.   

Abstract

BACKGROUND: The strong correlation between central histaminergic and cholinergic pathways on cognitive processes has been reported extensively. However, the role of histamine H(3) receptor mechanisms interacting with nicotinic mechanisms has not previously been extensively investigated.
METHODS: The current study was conducted to determine the interactions of nicotinic and histamine H(3) receptor systems with regard to learning and memory function using a modified elevated plus-maze test in mice. In this test, the latency for mice to move from the open arm to the enclosed arm (i.e., transfer latency) was used as an index of memory. We tested whether ABT-239 (4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl), an H(3) receptor antagonist/inverse agonist, had influence on two different stages of memory, i.e., memory acquisition and consolidation (administered prior to or immediately after the first trial, respectively) and whether ABT-239 influenced nicotine-induced memory enhancement.
RESULTS: Our results revealed that the acute administration of nicotine (0.035 and 0.175 mg/kg), but not of ABT-239 (0.1-3 mg/kg) reduced transfer latency in the acquisition and consolidation phases. In combination studies, concomitant administration of either ABT-239 (1 and 3 mg/kg) and nicotine (0.035 mg/kg), or ABT-239 (0.1 mg/kg) and nicotine (0.0175 mg/kg) further increased nicotine-induced improvement in both memory acquisition and consolidation.
CONCLUSION: The present data confirm an important role for H(3) receptors in regulating nicotine-induced mnemonic effects since inhibition of H(3) receptors augmented nicotine-induced memory enhancement in mice.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23406742     DOI: 10.1016/s1734-1140(12)70929-5

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  3 in total

1.  Translational and Early Phase Strategies for Treatment Development: Report of ISCTM Autumn 2013 Symposium.

Authors:  Jared W Young; William Z Potter; Steve Riley; Geert J Groeneveld; Bruce J Kinon; Mike F Egan; Douglas E Feltner
Journal:  Innov Clin Neurosci       Date:  2015 Mar-Apr

Review 2.  Therapeutic Potential of Histamine H3 Receptors in Substance Use Disorders.

Authors:  Patricia Di Ciano; Christian S Hendershot; Bernard Le Foll
Journal:  Curr Top Behav Neurosci       Date:  2022

3.  Histaminergic modulation of cholinergic release from the nucleus basalis magnocellularis into insular cortex during taste aversive memory formation.

Authors:  Liliana Purón-Sierra; María Isabel Miranda
Journal:  PLoS One       Date:  2014-03-13       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.